Skip to main content
eScholarship
Open Access Publications from the University of California

Dermatology Online Journal

Dermatology Online Journal bannerUC Davis

The continued inappropriate use and overuse of combination topical clotrimazole-betamethasone

  • Author(s): Flint, Nicholas D;
  • Rhoads, Jamie L W;
  • Carlisle, Ryan;
  • Ferrel, Meganne;
  • Hopkins, Zachary H;
  • Secrest, Aaron M
  • et al.
Abstract

Objective: Combination topical clotrimazole/ betamethasone dipropionate (C-BM) contains a high-potency topical corticosteroid and is not infrequently prescribed for inappropriate patient groups and body sites. Use of C-BM can lead to inadequate clearance or exacerbation of fungal infections as well as cutaneous atrophy, striae, and other skin maladies. Methods: We performed a retrospective chart review of 1,978 clinical visits where C-BM was prescribed within the University of Utah Health system between 2014 and 2018 to better understand current prescribing patterns. Results: 1,974 prescriptions were written for C-BM. 91.6% of patients were at least the recommended age of 17 years. C-BM was most commonly prescribed for rashes of an inflammatory (42.2%) or fungal nature (38.1%). Clotrimazole/betamethasone dipropionate was prescribed for sensitive areas (face, axillae, groin or diaper region) in 48.9% of patients. Family medicine clinicians prescribed 58.3% of C-BM prescriptions, whereas dermatology clinicians accounted for 3.4%. Conclusion: We strongly recommend clinicians use alternative treatments for rashes or refer to dermatologists.

Main Content
For improved accessibility of PDF content, download the file to your device.
Current View